The PAI-1/Vitronectin Interaction: Two Cats in a Bag?

Gang Deng; Gordon Royle; Dietmar Seiffert; David J Loskutoff

doi:10.1055/s-0038-1642654

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1995; 74(01): 066-070
DOI: 10.1055/s-0038-1642654

Symposium

Natural Inhibitors of Fibrinolysis

Schattauer GmbH Stuttgart

The PAI-1/Vitronectin Interaction: Two Cats in a Bag?

Gang Deng

Department of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA

,

Gordon Royle

Department of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA

,

Dietmar Seiffert

Department of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA

,

David J Loskutoff

Department of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA

› Author Affiliations

Abstract

PDF Download

PDF (381 kb)

References

References
1 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 190: 381-387
2 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. In: Progress in Hemostasis and Thrombosis. Coller B. ed. Vol 9 W.B.Saunders; Philadelphia, PA: 1989: 87-115
3 Schneiderman J, Loskutoff DJ. Plasminogen activator inhibitors. Trends Cardiovascular Med 1991; 1: 99-102
4 Dano K, Andreasen P, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266
5 Vassalh J-D, Sappino A-P, Berlin D. The plasminogen activator/plasmin system. J din Invest 1991; 88: 1067-1072
6 Carrell R, Travis J. a₁-Antitrypsin and the serpins: variation and countervariation. TIBS 1985; 20-24
7 Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen ativators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-11587
8 Declerck PJ, De Mol M, Alessi M-C, Baudner S, Paques E-P, Preissner KT, Muller-Berghaus G, Collen D. Purfication and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J Biol Chem 1988; 263: 15454-15461
9 Wiman B, Almquist A, Sigurdardottir O, Lindahl T. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma. FEBS Lett 1988; 242: 125-128
10 Mimuro J, Loskutoff DJ. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. J Biol Chem 1989; 264: 936-939
11 Preissner KT, Grulich-Henn J, Ehrlich HJ, Declerck P, Justus C, Collen D, Pannekoek H, Muller-Berghaus G. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 1990; 265: 18490-18498
12 Seiffert D, Wagner NN, Loskutoff DJ. Seru-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor. J Cell Biol 1990; 111: 1283-1291
13 Seiffert D, Loskutoff DJ. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem 1991; 266: 2824-2830
14 Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 1987; 70: 721-728
15 Kost C, Stuber W, Ehrlich HJ, Pannekoek H, Preissner KT. Mapping of binding sites forheparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin’s heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin foimation. J Biol Chem 1992; 267: 12098-12105
16 Mimuro J, Muramatsu S, Kurano Y, Uchida Y, Ikadai H, Watanabe S, Sakata Y. Identification of the plasminogen activator inhibitor-1 binding heptapeptide in vitronectin. Biochemistiy 1993; 32: 2314-2320
17 Tomasini BR, Mosher DF. Vitronectin. In: Progress in Hemostasis and Thrombosis. Coller B. ed. Vol (10) W.B.Saunders; Philadelphia, PA: 1990. 10. 269-305
18 Sigurdardottir O, Wiman B. Identification of a PAI-1 binding site in vitronectin. Biochim Biophys Acta 1994; 1208: 104-110
19 Lawrence DA, Beikenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 1994; 269: 15223-15228
20 Ciambrone G, Loskutoff DJ. unpublished observations
21 van Meijer M, Gebbink RK, Preissner KT, Pannekoek H. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1). FEBS Lett 1994; 352: 342-346
22 Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-273
23 Ehrlich HJ, Gebbink RK, Keijer J, Pannekoek H. Elucidation of structural requirements of plasminogen activator inhibitor 1 for binding to heparin. J Biol Chem 1992; 267: 11606-11611
24 Nakashima N, Miyazaki K, Ishikawa M, Yatohgo T, Ogawa H, Uchibori H, Matsumoto I, Seno N, Hayashi M. Vitronectin diversity in evolution but uniformity in ligand binding and size of the core polypeptide. Biochim Biophys Acta 1992; 1120: 1-10
25 Fiyklund L, Uthne K, Sievertsson H. Isolation and characterization of polypeptides from human plasma enhancing the growth of human normal cells in culture. Biochem Biophys Res Comm 1974; 61: 950-956
26 Heldin C-H, Fryklund L. Somatomedin B: Mitogenic activity derived from contaminant epidermal growth factor. Science 1981; 213: 1121-1123
27 Suzuki S, Oldberg A, Hayman EG, Pierschbacher MD, Ruoslahti E. Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J 1985; 4: 2519-2524
28 Salonen E-M, Vaheri A, Pollanen J, Stephens R, Andreasen P, Mayer M, Dano K, Gailit J, Ruoslahti E. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 1989; 264: 6339-6343
29 Sigurdardottir O, Wiman B. Studies on the interaction between plasminogen inhibitor-1 and vitronectin. Fibrinolysis 1992; 6: 27-32
30 Seiffert D, Loskutoff DJ. Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terimal fragment of bovine vitronectin. Biochim Biophys Acta 1991; 1078: 23-30
31 Seiffert D, Ciambrone G, Wagner NV, Binder BR, Loskutoff DJ. The somatomedin B domain of vitronectin. J Biol Chem 1994 269: 2659-2666
32 Tomassini-Johansson BR, Ruoslahti E, Pierschbacher MD. A 30 kD sulfated extracellular matrix protein immunologically crossreactive with vitronectin. Matrix 1993; 13: 203-214
33 Gechtman Z, Shaima R, Kreizman T, Fridkin M, Shaltiel S. Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin. FEBS Lett 1993; 315: 293-297
34 Wagner O, de Vries C, Hohmann C, Veerman H, Pannekoek H. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). J Clin Invest 1989; 84: 647-655
35 Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastractural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81: 1290-1299
36 Reilly CF, Hutzelmann JE. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissociation. J Biol Chem 1992; 267: 17128-17135
37 Lambers JW J, Cammenga M, Konig B, Pannekoek H, van Mourik JA. Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids. J Biol Chem 1987; 262: 17492-17496
38 Kruithof EK, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations cm its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-1653
39 Decleik PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225
40 Woolf N. Thrombosis and atherosclerosis. In: Heamostasis and Thrombosis. Bloom AL, Thomas DP. eds Churchill Livingstone; Edinburgh: 1981: 527-553
41 Levi M, Biemond BJ, Van Zooneveld AJ, Woulter ten Cate J, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305
42 Potter van Loon BJ, Rijken DC, Broomer EJ P, Van der Maas AP C. The amount of plasminogen, tissue type plasminogen activatorand plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost 1992; 67: 101
43 Merberg DM, Fitz U, Temple P, Giannotti J, Murtha P, Fitzgerald M, Scaltreto J, Kelleher K, Preissner K, Kriz R, Jacobs K, Turner K. A comparison of vitronectin and megakaryocyte stimulating factor. In: Biology of Vitronectins and their Receptors. Rosenblatt S, Preissner KR, Kost C, Wegerhoff J, Mosher DF. eds. Elsevier Science Publishers B.V.; The Netherlands: 1993: 45-55
44 Grundmann U, Romisch J, Siebold B, Bohn H, Amann E. Cloning and expression of a cDNA encoding human placental protein 11, a putative serine protease with diagnostic significance as a tumor marker. DNA Cell Biol 1990; 9: 243-250
45 Baughman G, Lesley J, Trotter J, Hyman R, Bourgeois S. Tcl-30, a new T cell-specific gene expressed in immature glucocorticoid-sensitive thymocytes. J Immunol 1992; 149: 1488-1496
46 Buckley MF, Loveland KA, McKinstry WJ, Garson OM, Goding JW. Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location. J Biol Chem 1990; 265: 17506-17511
47 Seiffert D, Keeton M, Eguchi Y, Sawdey M, Loskutoff DJ. Detection of vitronectin mRNA in tissues and cells of the mouse. Proc Natl Acad Sci USA 1991; 88: 9402-9406